Table 2.
Stage 1→ Stage 2 | Stage 1→ Stage 4 | Stage 2→ Stage 3 | Stage 2→ Stage 4 | Stage 3→ Stage 4 | |
---|---|---|---|---|---|
Age at baseline | 1.08 (1.06–1.10)* | 0.99 (0.95–1.03) | 1.00 (0.97–1.02) | 1.02 (0.99–1.06) | 1.00 (0.98–1.02) |
Male sex | 1.08 (0.86–1.36) | 1.15 (0.73–1.81) | 1.01 (0.72–1.41) | 0.87 (0.52–1.43) | 1.40 (1.04–1.89)* |
Education | 0.93 (0.91–0.96)* | 1.01 (0.95–1.07) | 0.99 (0.95–1.03) | 1.00 (0.95–1.06) | 1.03 (1.00–1.07) |
AD | 1.36 (1.07–1.72)* | 0.40 (0.24–0.66)* | 1.95 (1.30–2.92)* | 0.38 (0.23–0.61)* | 0.81 (0.57–1.16) |
Macro infarcts | 1.38 (1.12–1.72)* | 0.56 (0.31–1.04) | 1.50 (1.12–2.02)* | 0.33 (0.18–0.62)* | 0.98 (0.75–1.28) |
Lewy bodies | 1.17 (0.93–1.48) | 0.58 (0.29–1.14) | 1.48 (1.08–2.03)* | 0.60 (0.31–1.16) | 0.77 (0.58–1.03) |
1. Stage 1, no impairment; Stage 2, mild impairment; Stage 3, moderate impairment; Stage 4, death.
2. The reference group refers to female participants with age 80 at baseline, with 15 years of education, and without any of the three neuropathologic findings.
3. *Hazard ratios that were statistically significant at α=0.05.